医学
阶段(地层学)
癌症
肺癌
中心(范畴论)
肿瘤科
过继性细胞移植
肺
细胞
癌症研究
内科学
T细胞
生物
免疫学
免疫系统
化学
遗传学
古生物学
结晶学
作者
Michael T. Lotze,Markus Maeurer,Sergio A. Quezada,George Coukos
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2024-08-02
卷期号:14 (8): 1366-1368
被引量:1
标识
DOI:10.1158/2159-8290.cd-24-0645
摘要
Schoenfeld and colleagues report, in this issue, a measurable objective response rate in 6/28 (21.4%) of patients with advanced non-small cell lung cancer treated with lifileucel, a cell therapy product based on autologous tumor-infiltrating lymphocytes (TIL). Extending solid evidence in advanced melanoma that led to FDA approval of lifileucel, this new evidence bodes well for treating patients with other common tumor histologies, justifying important efforts by a large number of academic and biotechnology companies engaged in improving the TIL process. See related article by Schoenfeld et al., p. 1389 (1).
科研通智能强力驱动
Strongly Powered by AbleSci AI